Clinical Trials Browser

Completed × Interventional × Gefitinib × Clear all

NCT03758287 2026-05-12

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-04-21

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT00328562 2025-05-04

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

13 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT01513174 2024-06-28

GOAL

Phase 1/2 Completed

186 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT00198380 2024-03-08

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

Phase 2 Completed

Adenocarcinoma, Bronchiolo-Alveolar

NCT01185158 2023-11-29

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Phase 2 Completed

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

452 enrolled 35 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04642547 2023-08-01

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Phase NA Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT01833572 2023-07-12

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01185171 2023-05-11

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

Phase 2 Completed

70 enrolled 11 charts

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT01570296 2023-03-29

BKM120

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT01982955 2022-11-08

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Phase 1/2 Completed

88 enrolled 45 charts

Carcinoma, Non-Small-Cell Lung

NCT02039674 2022-11-08

MK-3475-021

Phase 1/2 Completed

267 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT02447419 2022-06-15

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Phase 2 Completed

Other solid neoplasm

Solid Tumor

NCT03170180 2022-06-15

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT02088112 2022-04-04

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00317772 2022-02-07

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 1/2 Completed

19 enrolled 12 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02804776 2021-06-02

PROGRESS

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Phase 2 Completed

161 enrolled 32 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01556191 2021-01-08

LADIE

Phase 2 Completed

Lung Neoplasms

NCT00052208 2020-10-30

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

Phase 1/2 Completed

Glioblastoma, Gliosarcoma

NCT01544179 2020-09-25

IMPRESS

Phase 3 Completed

265 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT02374645 2020-04-24

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT01466660 2020-04-07

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Phase 2 Completed

319 enrolled 19 charts

Lung Neoplasms

NCT00025116 2020-04-06

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Completed

Prostatic Neoplasms

NCT01933347 2020-02-06

Third-line Treatment of Gefitinib in NSCLC Patients

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Completed

NSCLC

NCT00014183 2019-11-07

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01469000 2019-09-10

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

195 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT00126555 2019-08-30

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Phase 2 Completed

23 enrolled 12 charts

Skin Neoplasms

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Phase 2 Completed

32 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00027690 2019-07-23

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Phase 2 Completed

Recurrent Uterine Corpus Carcinoma

NCT02889692 2019-04-11

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Phase 3 Completed

Lung Neoplasms, Neoplasms

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

Neoplasm Metastasis

NCT00027625 2018-06-27

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00025675 2018-06-26

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT01864681 2018-06-20

CGMT

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00215202 2018-05-17

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Phase 2 Completed

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms

NCT00372515 2018-01-31

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00509002 2017-11-24

Iressa Study in Patients With Salivary Gland Cancer

Phase 2 Completed

37 enrolled 4 charts

Salivary Gland Neoplasms

NCT00452244 2017-08-25

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Lung Neoplasms

NCT00095836 2017-05-31

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Phase 2 Completed

27 enrolled 16 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT00310154 2017-05-30

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 1 Completed

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03157310 2017-05-17

Bone Metastasis on the Survival of Gefitinib Effective Patients

Phase NA Completed

Carcinoma, Non-Small-Cell Lung

NCT00186979 2017-04-26

Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumors

NCT00188617 2017-03-14

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Phase 2 Completed

Lung Neoplasms

NCT00231465 2017-03-03

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

Phase 2 Completed

44 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT01024413 2017-03-01

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Phase 3 Completed

Lung Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT00086957 2017-02-27

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

31 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male